The abstract is read at the publisher; the summary is JClub's.
Parenteral glucocorticoids in early rheumatoid arthritis are linked to lower odds of persistent steroid use at 12 months (OR 4.1 vs oral OR 9.8).
- Why it matters: It is unclear whether giving glucocorticoids by injection versus by mouth changes longer-term steroid persistence or the need to escalate treatment in early rheumatoid arthritis.
- What they did: In the Canadian Early Arthritis Cohort (2007–2023), adults with newly diagnosed early rheumatoid arthritis were stratified by glucocorticoid route in the first 3 months and analyzed with adjusted multivariable logistic regression for 12-month outcomes.
- The result: At 12 months, advanced therapy use was similar across routes (7% no GC, 14% oral, 14% parenteral, 16% both), while odds of glucocorticoid use were lower with parenteral than oral.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.